A
Akram Khan
Researcher at Oregon Health & Science University
Publications - 104
Citations - 5848
Akram Khan is an academic researcher from Oregon Health & Science University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 25, co-authored 59 publications receiving 2487 citations. Previous affiliations of Akram Khan include Mayo Clinic & University of Florida Health Science Center.
Papers
More filters
Journal ArticleDOI
Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network - United States, March-June 2020.
Mark W Tenforde,Sara S. Kim,Christopher J. Lindsell,Erica Billig Rose,Nathan I. Shapiro,D. Clark Files,Kevin W Gibbs,Heidi L Erickson,Jay S. Steingrub,Howard A. Smithline,Michelle N. Gong,Michael S. Aboodi,Matthew C. Exline,Daniel J. Henning,Jennifer G. Wilson,Akram Khan,Nida Qadir,Samuel M. Brown,Ithan D. Peltan,Todd W. Rice,David N. Hager,Adit A. Ginde,William B. Stubblefield,Manish M. Patel,Wesley H. Self,Leora R. Feldstein +25 more
TL;DR: It is indicated that COVID-19 can result in prolonged illness even among persons with milder outpatient illness, including young adults, and effective public health messaging targeting these groups is warranted.
Journal ArticleDOI
A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome
Akram Khan,Cody Benthin,Brian Zeno,Timothy E Albertson,John H. Boyd,Jason D. Christie,Richard I. Hall,Germain Poirier,Juan J. Ronco,Mark Tidswell,Kelly Hardes,William Powley,Tracey J. Wright,Sarah Siederer,David Fairman,David A. Lipson,David A. Lipson,Andrew I. Bayliffe,Aili L. Lazaar,Aili L. Lazaar +19 more
TL;DR: GSK2586881 was well-tolerated in patients with ARDS, and the rapid modulation of RAS peptides suggests target engagement, although the study was not powered to detect changes in acute physiology or clinical outcomes.
Journal ArticleDOI
Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study
Adam S. Lauring,Mark W Tenforde,James D. Chappell,Manjusha Gaglani,Adit A. Ginde,Tresa McNeal,Shekhar Ghamande,David J. Douin,H. Keipp Talbot,Jonathan D Casey,Nicholas M. Mohr,Anne Zepeski,Nathan I. Shapiro,Kevin W Gibbs,D. Clark Files,David N. Hager,Arber N. Shehu,Matthew E. Prekker,Heidi L Erickson,Matthew C. Exline,Michelle N. Gong,Amira H. Mohamed,Nicholas J. Johnson,Vasisht Srinivasan,Jay S. Steingrub,Ithan D. Peltan,Samuel M. Brown,Emily T. Martin,Arnold S. Monto,Akram Khan,Catherine L. Hough,Laurence W. Busse,C. T. ten Lohuis,Abhijit Duggal,Jennifer G. Wilson,Alexandra June Gordon,Nida Abdul Qadir,Steven Y. Chang,Christopher Mallow,Carolina Gutiérrez Rivas,Hilary M. Babcock,Jennie H. Kwon,Natasha B. Halasa,Carlos G. Grijalva,Todd W. Rice,William B. Stubblefield,Adrienne Baughman,Kelsey N Womack,Jillian P. Rhoads,Christopher J. Lindsell,Kimberly W. Hart,Yuwei Zhu,K. Adams,Stephanie J. Schrag,Samantha M. Olson,M. Kobayashi,Jennifer R. Verani,Manish M. Patel,Wesley H. Self +58 more
TL;DR:
Journal ArticleDOI
Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity.
Mark W Tenforde,Wesley H. Self,Katherine Adams,Manjusha Gaglani,Adit A. Ginde,Tresa McNeal,Shekhar Ghamande,David J. Douin,H. Keipp Talbot,Jonathan D Casey,Nicholas M. Mohr,Anne Zepeski,Nathan I. Shapiro,Kevin W Gibbs,D. Clark Files,David N. Hager,Arber Shehu,Matthew E. Prekker,Heidi L Erickson,Matthew C. Exline,Michelle N. Gong,Amira Mohamed,Daniel J. Henning,Jay S. Steingrub,Ithan D. Peltan,Samuel M. Brown,Emily T. Martin,Arnold S. Monto,Akram Khan,Catherine L. Hough,Laurence W. Busse,Caitlin C Ten Lohuis,Abhijit Duggal,Jennifer G. Wilson,Alexandra June Gordon,Nida Qadir,Steven Y. Chang,Christopher Mallow,Carolina Rivas,Hilary M. Babcock,Jennie H. Kwon,Natasha B. Halasa,James D. Chappell,Adam S. Lauring,Carlos G. Grijalva,Todd W. Rice,Ian Jones,William B Stubblefield,Adrienne Baughman,Kelsey N Womack,Jillian P. Rhoads,Christopher J. Lindsell,Kimberly W. Hart,Yuwei Zhu,Samantha M. Olson,Miwako Kobayashi,Jennifer R. Verani,Manish M. Patel,Influenza +58 more
TL;DR: In this article, the authors evaluated the association between vaccination with mRNA COVID-19 vaccines and hospitalization, and the association with progression to critical disease, using multivariable logistic regression.
Journal ArticleDOI
Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial.
Wesley H. Self,Matthew W. Semler,Lindsay M. Leither,Lindsay M. Leither,Jonathan D Casey,Derek C. Angus,Roy G. Brower,Steven Y. Chang,Sean P. Collins,John Eppensteiner,Michael R. Filbin,D. Clark Files,Kevin W Gibbs,Adit A. Ginde,Michelle N. Gong,Frank E. Harrell,Douglas Hayden,Catherine L. Hough,Nicholas J. Johnson,Akram Khan,Christopher J. Lindsell,Michael A. Matthay,Marc Moss,Pauline K. Park,Todd W. Rice,Bryce R.H. Robinson,David A. Schoenfeld,Nathan I. Shapiro,Jay S. Steingrub,Christine A. Ulysse,Alexandra Weissman,Donald M. Yealy,B. Taylor Thompson,Samuel M. Brown,Samuel M. Brown +34 more
TL;DR: Among adults hospitalized with respiratory illness from COVID-19, treatment with hydroxychloroquine, compared with placebo, did not significantly improve clinical status at day 14, and these findings do not support the use of hydroxy chloroquine for treatment of CO VID-19 among hospitalized adults.